Long-term treatment with subcutaneous T-20, a fusion inhibitor, in HIV-infected patients: Patient satisfaction and impact on activities of daily living

AIDS Patient Care and STDs

Volumn 16, Issue 7, 2002, Pages 327-335

  Cohen, Calvin J ^a   Dusek, A ^b   Green, J ^c   Johns, E L ^d   Nelson, E ^b   Recny, M A ^b  

^a Boston Community Research Initiative of New England   (United States)

^b Trimeris Inc   (United States)

^c HOFFMANN LA ROCHE INC   (United States)

^d BioStrategies Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; ENFUVIRTIDE;

ADULT; ARTICLE; CLINICAL TRIAL; DAILY LIFE ACTIVITY; DRUG SAFETY; DRUG SELF ADMINISTRATION; DRUG WITHDRAWAL; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LONG TERM CARE; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; PATIENT SATISFACTION; PHASE 2 CLINICAL TRIAL; QUESTIONNAIRE; SIDE EFFECT; VIRUS CELL INTERACTION; VIRUS LOAD;

ACTIVITIES OF DAILY LIVING; ADULT; ANTI-HIV AGENTS; FEMALE; HIV ENVELOPE PROTEIN GP41; HIV FUSION INHIBITORS; HIV INFECTIONS; HUMANS; INJECTIONS, SUBCUTANEOUS; MALE; PATIENT SATISFACTION; PEPTIDE FRAGMENTS; QUESTIONNAIRES; SELF ADMINISTRATION;

EID: 0036315615     PISSN: 10872914     EISSN: None     Source Type: Journal    
DOI: 10.1089/108729102320231162     Document Type: Article

References (22)

1. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection
2. Antiretroviral therapy in adults: Updated recommendations of the International AIDS Society-USA Panel
3. A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4+ cell counts of 200 per cubic millimeter or less
4. Treatment with indinavir, zidovudine, and lamivudine in adults with human immunodeficiency virus infection and prior antiretroviral therapy
5. A randomized, double-blind trial comparing combinations of nevirapine, didanosine, and zidovudine for HIV-infected patients: The INCAS Trial
6. HIV-Protease Inhibitors
7. Antiretroviral drug resistance testing in adults with HIV infection: Implications for clinical management
8. Structure of an HIV gp120 envelope glycoprotein in complex with the CD4+ receptor and a neutralizing antibody
9. Core structure of gp41 from the HIV envelope glycoprotein
10. A synthetic peptide from HIV-1 gp41 is a potent inhibitor of virus-mediated cell-cell fusion
11. Potent suppression of HIV-1 replication in humans by T-20, a peptide inhibitor of gp41-mediated virus entry
12. Prolonged therapy with the fusion inhibitor T-20 in combination with oral antiretroviral agents in an HIV-infected individual
13. Safety, pharmacokinetics and antiviral activity of T-20 as a single agent in heavily pre-treated patients
14. Forty-eight week analysis of patients receiving T20 as a component of multi-drug salvage therapy
15. The Functional Assessment of Cancer Therapy scale: Development and validation of the general measure
16. Assessment of adaptive functioning in Huntington's Disease
17. Health accounting-Functional assessment of the long-term patient
18. Progress in development of the index of ADL
19. Barriers to adherence to highly active antiretroviral therapy as expressed by people living with HIV/AIDS
20. Factors affecting adherence to antiretroviral therapy
21. Long-term patient adherence to antiretroviral therapy
22. Development and validation of the Functional Assessment of Human Immunodeficiency Virus Infection (FAHI) quality of life instrument